Seoul, South Korea · Founded 2018 · Privately Held (backing)
Developer of an adeno-associated virus (AAV) gene therapy designed to improve the quality of life of patients. Elisigen is based in Seoul, South Korea and was founded in 2018. Its last reported valuation was $74.5 million in Jul 2021. It has raised $83.7 million.
Last reported valuation
$74.5M
Oct 2026
Priced at
—
Total raised
$83.7M
Last round
—
Cap table — not yet on record
Elisigen's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Elisigen with a free account
·The complete investor list: 24 names
·Watch Elisigen: the Monday email on marks, rounds and moves
